BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

303 related articles for article (PubMed ID: 30861596)

  • 1. Patterns of endocrine therapy in a national cohort of early stage HER2-positive breast cancer patients.
    Tervonen HE; Daniels B; Tang M; Preen DB; Pearson SA
    Pharmacoepidemiol Drug Saf; 2019 Jun; 28(6):812-820. PubMed ID: 30861596
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-world patterns of endocrine therapy for metastatic hormone-receptor-positive (HR+)/human epidermal growth factor receptor-2-negative (HER2-) breast cancer patients in the United States: 2002-2012.
    Swallow E; Zhang J; Thomason D; Tan RD; Kageleiry A; Signorovitch J
    Curr Med Res Opin; 2014 Aug; 30(8):1537-45. PubMed ID: 24669852
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Does guideline non-adherence result in worse clinical outcomes for hormone receptor-positive and HER2-negative metastatic breast cancer in premenopausal women?: result of an institution database from South Korea.
    Kim HK; Lee SH; Kim YJ; Park SE; Lee HS; Lim SW; Cho JH; Kim JY; Ahn JS; Im YH; Yu JH; Park YH
    BMC Cancer; 2019 Jan; 19(1):84. PubMed ID: 30654765
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Early discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8,769 early-stage breast cancer patients.
    Hershman DL; Kushi LH; Shao T; Buono D; Kershenbaum A; Tsai WY; Fehrenbacher L; Gomez SL; Miles S; Neugut AI
    J Clin Oncol; 2010 Sep; 28(27):4120-8. PubMed ID: 20585090
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adherence to prescribing restrictions for HER2-positive metastatic breast cancer in Australia: A national population-based observational study (2001-2016).
    Daniels B; Girosi F; Tervonen H; Kiely BE; Lord SJ; Houssami N; Pearson SA
    PLoS One; 2018; 13(7):e0198152. PubMed ID: 30048453
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Extended adjuvant aromatase inhibition after sequential endocrine therapy (DATA): a randomised, phase 3 trial.
    Tjan-Heijnen VCG; van Hellemond IEG; Peer PGM; Swinkels ACP; Smorenburg CH; van der Sangen MJC; Kroep JR; De Graaf H; Honkoop AH; Erdkamp FLG; van den Berkmortel FWPJ; de Boer M; de Roos WK; Linn SC; Imholz ALT; Seynaeve CM;
    Lancet Oncol; 2017 Nov; 18(11):1502-1511. PubMed ID: 29031778
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adherence trajectories of adjuvant endocrine therapy in the five years after its initiation among women with non-metastatic breast cancer: a cohort study using administrative databases.
    Lambert-Côté L; Bouhnik AD; Bendiane MK; Bérenger C; Mondor M; Huiart L; Lauzier S
    Breast Cancer Res Treat; 2020 Apr; 180(3):777-790. PubMed ID: 32086655
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current Treatment Patterns Among Postmenopausal Women with HR+/HER2- Metastatic Breast Cancer in US Community Oncology Practices: An Observational Study.
    Goldschmidt D; Dalal AA; Romdhani H; Kelkar S; Guerin A; Gauthier G; Wu EQ; Niravath P; Small T
    Adv Ther; 2018 Apr; 35(4):482-493. PubMed ID: 29582246
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Persistence and discontinuation of adjuvant endocrine therapy in women with breast cancer.
    Kuba S; Ishida M; Nakamura Y; Taguchi K; Ohno S
    Breast Cancer; 2016 Jan; 23(1):128-133. PubMed ID: 24934610
    [TBL] [Abstract][Full Text] [Related]  

  • 10. First-line endocrine therapy alone could be a reasonable treatment option for hormone-positive, HER2-positive metastatic breast cancer.
    Peron J; Tredan O; Ray-Coquard I; Bachelot T; Labidi Galy SI; Favier B; Treilleux I; Guastalla JP
    Bull Cancer; 2012 Feb; 99(2):E18-25. PubMed ID: 22257781
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patient-reported discontinuation of endocrine therapy and related adverse effects among women with early-stage breast cancer.
    Aiello Bowles EJ; Boudreau DM; Chubak J; Yu O; Fujii M; Chestnut J; Buist DS
    J Oncol Pract; 2012 Nov; 8(6):e149-57. PubMed ID: 23598850
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Five-Year Adjuvant Endocrine Therapy Adherence Trajectories Among Women With Breast Cancer: A Nationwide French Study Using Administrative Data.
    Lailler G; Memoli V; Le Bihan Benjamin C; Ben Diane MK; Lauzier S; Mancini J; Bousquet PJ; Bouhnik AD
    Clin Breast Cancer; 2021 Aug; 21(4):e415-e426. PubMed ID: 33745868
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment Restarting After Discontinuation of Adjuvant Hormone Therapy in Breast Cancer Patients.
    He W; Smedby KE; Fang F; Olsson H; Margolin S; Hall P; Czene K
    J Natl Cancer Inst; 2017 Oct; 109(10):. PubMed ID: 28423398
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Five-year patterns of adjuvant hormonal therapy use, persistence, and adherence among insured women with early-stage breast cancer.
    Nekhlyudov L; Li L; Ross-Degnan D; Wagner AK
    Breast Cancer Res Treat; 2011 Nov; 130(2):681-9. PubMed ID: 21842245
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Age-related differences in persistence in women with breast cancer treated with tamoxifen or aromatase inhibitors in Germany.
    Jacob L; Hadji P; Kostev K
    J Geriatr Oncol; 2016 May; 7(3):169-75. PubMed ID: 27091510
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adherence to Adjuvant Endocrine Therapy in Women With Breast Cancer: A Prospective Observational Study in Japanese Women.
    Kuba S; Maeda S; Matsumoto M; Yamanouchi K; Yano H; Morita M; Sakimura C; Hatachi T; Tokai Y; Takatsuki M; Fujioka H; Hayashida N; Nagayasu T; Eguchi S
    Clin Breast Cancer; 2018 Apr; 18(2):150-156. PubMed ID: 29290564
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Endocrine therapy or chemotherapy as first-line therapy in hormone receptor-positive HER2-negative metastatic breast cancer patients.
    Jacquet E; Lardy-Cléaud A; Pistilli B; Franck S; Cottu P; Delaloge S; Debled M; Vanlemmens L; Leheurteur M; Guizard AV; Laborde L; Uwer L; Jacot W; Berchery D; Desmoulins I; Ferrero JM; Perrocheau G; Courtinard C; Brain E; Chabaud S; Robain M; Bachelot T
    Eur J Cancer; 2018 May; 95():93-101. PubMed ID: 29655061
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patterns of Care and Clinical Outcomes of HER2-positive Metastatic Breast Cancer Patients With Newly Diagnosed Stage IV or Recurrent Disease Undergoing First-line Trastuzumab-based Therapy: A Multicenter Retrospective Cohort Study.
    Lambertini M; Ferreira AR; Di Meglio A; Poggio F; Puglisi F; Sottotetti F; Montemurro F; Poletto E; Bernardo A; Risi E; Dellepiane C; Sini V; Minuti G; Grasso D; Fancelli S; Del Mastro L
    Clin Breast Cancer; 2017 Dec; 17(8):601-610.e2. PubMed ID: 28479052
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adherence to Adjuvant Endocrine Therapy in Christchurch Women with Early Breast Cancer.
    Robinson B; Dijkstra B; Davey V; Tomlinson S; Frampton C
    Clin Oncol (R Coll Radiol); 2018 Jan; 30(1):e9-e15. PubMed ID: 29103853
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oncologists' recommendations for adjuvant therapy in hormone receptor-positive breast cancer patients of varying age and health status.
    Naeim A; Wong FL; Pal SK; Hurria A
    Clin Breast Cancer; 2010 Apr; 10(2):136-43. PubMed ID: 20353934
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.